Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update

Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis

(2021) Xiaochen Lin et al.   BMC Neurology

Responder analysis for neuropathic impairment and quality-of-life assessment in patients with hereditary transthyretin amyloidosis with polyneuropathy in the NEURO-TTR study

(2021) Aaron Yarlas et al.   JOURNAL OF NEUROLOGY

Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR

(2021) Aaron Yarlas et al.   Neurology and Therapy

Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy

(2020) David Adams et al.   JOURNAL OF NEUROLOGY

Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study

(2020) Mónica Inês et al.   Orphanet Journal of Rare Diseases

Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial

(2020) T. H. Brannagan et al.   EUROPEAN JOURNAL OF NEUROLOGY

What Are the Minimum Clinically Important Differences in SF-36 Scores in Patients with Orthopaedic Oncologic Conditions?

(2020) Koichi Ogura et al.   CLINICAL ORTHOPAEDICS AND RELATED RESEARCH

Advances in the treatment of hereditary transthyretin amyloidosis: A review

(2019) Morie A. Gertz et al.   Brain and Behavior

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

(2018) Merrill D. Benson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Minimum Clinically Important Difference in SF-36 Scores for Use in Degenerative Cervical Myelopathy

(2018) Jetan H. Badhiwala et al.   SPINE

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy

(2016) David Adams et al.   CURRENT OPINION IN NEUROLOGY

Genotype and Phenotype of Transthyretin Cardiac Amyloidosis

(2016) Mathew S. Maurer et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Clinical measures in transthyretin familial amyloid polyneuropathy

(2016) Teresa Coelho et al.   MUSCLE & NERVE

Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis

(2015) Morie A. Gertz et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Quality of life in ATTR amyloidosis

(2015) Thirusha Lane et al.   Orphanet Journal of Rare Diseases

THAOS: Gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease

(2014) Jonas Wixner et al.   Orphanet Journal of Rare Diseases

Usefulness of minimum clinically important difference for assessing patients with subaxial degenerative cervical spine disease: statistical versus substantial clinical benefit

(2013) Brenda Auffinger et al.   ACTA NEUROCHIRURGICA

THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis

(2012) Teresa Coelho et al.   CURRENT MEDICAL RESEARCH AND OPINION

Familial amyloid polyneuropathy

(2011) Violaine Planté-Bordeneuve et al.   LANCET NEUROLOGY